| Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database CS Vallejos, HL Gómez, WR Cruz, JA Pinto, RR Dyer, R Velarde, ... Clinical breast cancer 10 (4), 294-300, 2010 | 277 | 2010 |
| Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model K Naqvi, G Garcia-Manero, S Sardesai, J Oh, CE Vigil, S Pierce, X Lei, ... Journal of Clinical Oncology 29 (16), 2240, 2011 | 175 | 2011 |
| Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies … ST Mahmood, S Agresta, CE Vigil, X Zhao, G Han, G D'Amato, CE Calitri, ... International journal of cancer 129 (8), 1963-1969, 2011 | 137 | 2011 |
| Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies … ST Mahmood, S Agresta, CE Vigil, X Zhao, G Han, G D'Amato, CE Calitri, ... International journal of cancer 129 (8), 1963-1969, 2011 | 137 | 2011 |
| Current progress in targeted therapy for colorectal cancer J Ortega, CE Vigil, C Chodkiewicz Cancer control 17 (1), 7-15, 2010 | 107 | 2010 |
| Myelodysplastic syndromes and autoimmune diseases—case series and review of literature O Al Ustwani, LA Ford, SJN Sait, AMW Block, M Barcos, CE Vigil, ... Leukemia research 37 (8), 894-899, 2013 | 85 | 2013 |
| The Epstein-Barr virus (EBV) in T cell and NK cell lymphomas: time for a reassessment AA Gru, BH Haverkos, AG Freud, J Hastings, NB Nowacki, C Barrionuevo, ... Current hematologic malignancy reports 10, 456-467, 2015 | 80 | 2015 |
| The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome A McBride, S Houtmann, L Wilde, C Vigil, CM Eischen, M Kasner, ... Frontiers in oncology 9, 192, 2019 | 42 | 2019 |
| Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients≥ 60 years old N Gupta, A Miller, S Gandhi, LA Ford, CE Vigil, EA Griffiths, JE Thompson, ... American journal of hematology 90 (7), 639-646, 2015 | 39 | 2015 |
| Clinical use of FLT3 inhibitors in acute myeloid leukemia G Sutamtewagul, CE Vigil OncoTargets and therapy, 7041-7052, 2018 | 38 | 2018 |
| Safety and efficacy of azacitidine in myelodysplastic syndromes CE Vigil, T Martin-Santos, G Garcia-Manero Drug Design, Development and Therapy, 221-229, 2010 | 37 | 2010 |
| Interpretation of cytogenetic and molecular results in patients treated for CML CE Vigil, EA Griffiths, ES Wang, M Wetzler Blood reviews 25 (3), 139-146, 2011 | 34 | 2011 |
| Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer J Buleje, M Guevara‐Fujita, O Acosta, FDP Huaman, P Danos, A Murillo, ... Molecular genetics & genomic medicine 5 (5), 481-494, 2017 | 25 | 2017 |
| Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas CE Vigil, AA Chiappori, CA Williams, HH Shrager, BL Murray, DG Letson, ... Journal of Clinical Oncology 26 (15_suppl), 10535-10535, 2008 | 25 | 2008 |
| Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients HL Gómez, CA Castañeda, CE Vigil, T Vidaurre, RG Velarde, WR Cruz, ... Hematology/oncology and stem cell therapy 3 (3), 109-115, 2010 | 24 | 2010 |
| Younger patients with newly diagnosed FLT3-mutant AML treated with crenolanib plus chemotherapy achieve adequate free crenolanib levels and durable remissions AD Goldberg, CC Coombs, ES Wang, RB Walter, C Karanes, CE Vigil, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 20 | 2019 |
| Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML AD Goldberg, RH Collins, RM Stone, RB Walter, C Karanes, CE Vigil, ... Blood 132, 1436, 2018 | 15 | 2018 |
| Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML S de Botton, T Cluzeau, C Vigil, RJ Cook, P Rousselot, DA Rizzieri, ... Blood advances 7 (9), 1858-1870, 2023 | 14 | 2023 |
| Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer HL Gómez, JA Pinto, M Olivera, T Vidaurre, FD Doimi, CE Vigil, ... The Breast 20 (1), 39-45, 2011 | 13 | 2011 |
| Early results from a biomarker-directed phase 2 trial of Sy-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid … JG Jurcic, A Raza, G Vlad, EM Stein, M Roshal, DL Bixby, DF Boyer, ... Blood 130, 2633, 2017 | 12 | 2017 |
